Geode Capital Management
LRMR icon

Geode Capital Management’s Larimar Therapeutics LRMR Stock Holding History

Geode Capital Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.99M Buy
1,108,761
+15,438
+1% +$61.7K ﹤0.01% 2737
2025
Q4 		$4.17M Buy
1,093,323
+70,796
+7% +$275K ﹤0.01% 2870
2025
Q3 		$3.3M Buy
1,022,527
+118,102
+13% +$443K ﹤0.01% 2986
2025
Q2 		$2.61M Sell
904,425
-3,536
-0.4% -$8.19K ﹤0.01% 3051
2025
Q1 		$1.95M Buy
907,961
+21,547
+2% +$68.1K ﹤0.01% 3041
2024
Q4 		$3.43M Sell
886,414
-14,848
-2% -$98K ﹤0.01% 2925
2024
Q3 		$5.9M Sell
901,262
-237,861
-21% -$1.91M ﹤0.01% 2674
2024
Q2 		$8.26M Buy
1,139,123
+269,740
+31% +$2.07M ﹤0.01% 2446
2024
Q1 		$6.6M Buy
869,383
+221,665
+34% +$1.73M ﹤0.01% 2550
2023
Q4 		$2.95M Buy
647,718
+31,412
+5% +$106K ﹤0.01% 2961
2023
Q3 		$2.43M Buy
616,306
+79,746
+15% +$302K ﹤0.01% 3006
2023
Q2 		$1.68M Buy
536,560
+264,596
+97% +$1.08M ﹤0.01% 3165
2023
Q1 		$1.23M Buy
271,964
+41,173
+18% +$215K ﹤0.01% 3247
2022
Q4 		$953K Buy
230,791
+116,901
+103% +$399K ﹤0.01% 3363
2022
Q3 		$364K Hold
113,890
– – ﹤0.01% 3898
2022
Q2 		$223K Hold
113,890
– – ﹤0.01% 4195
2022
Q1 		$461K Hold
113,890
– – ﹤0.01% 3972
2021
Q4 		$1.23M Sell
113,890
-170
-0.1% -$1.89K ﹤0.01% 3606
2021
Q3 		$1.31M Buy
114,060
+1,606
+1% +$19.3K ﹤0.01% 3541
2021
Q2 		$1.1M Buy
112,454
+11,020
+11% +$125K ﹤0.01% 3541
2021
Q1 		$1.48M Buy
101,434
+16,027
+19% +$291K ﹤0.01% 3397
2020
Q4 		$1.83M Buy
85,407
+16,914
+25% +$339K ﹤0.01% 3132
2020
Q3 		$1.04M Buy
68,493
+42,630
+165% +$540K ﹤0.01% 3195
2020
Q2 		$332K Buy
25,863
+4,798
+23% +$55.9K ﹤0.01% 3507
2020
Q1 		$194K Sell
21,065
-550
-3% -$7.23K ﹤0.01% 3563
2019
Q4 		$287K Hold
21,615
– – ﹤0.01% 3691
2019
Q3 		$191K Sell
21,615
-47
-0.2% -$515 ﹤0.01% 3788
2019
Q2 		$309K Sell
21,662
-15,432
-42% -$411K ﹤0.01% 3641
2019
Q1 		$1.22M Buy
37,094
+2,012
+6% +$103K ﹤0.01% 3079
2018
Q4 		$2.08M Buy
35,082
+1,853
+6% +$183K ﹤0.01% 2750
2018
Q3 		$4.66M Buy
33,229
+16,517
+99% +$2M ﹤0.01% 2397
2018
Q2 		$2.05M Buy
16,712
+5,267
+46% +$447K ﹤0.01% 2848
2018
Q1 		$1.02M Buy
11,445
+1,905
+20% +$161K ﹤0.01% 3111
2017
Q4 		$528K Sell
9,540
-332
-3% -$15K ﹤0.01% 3338
2017
Q3 		$417K Sell
9,872
-78
-0.8% -$3.24K ﹤0.01% 3425
2017
Q2 		$419K Sell
9,950
-3,547
-26% -$181K ﹤0.01% 3416
2017
Q1 		$754K Buy
13,497
+1,506
+13% +$74.8K ﹤0.01% 3149
2016
Q4 		$457K Buy
11,991
+367
+3% +$14.9K ﹤0.01% 3297
2016
Q3 		$461K Buy
11,624
+8
+0.1% +$363 ﹤0.01% 3281
2016
Q2 		$834K Buy
11,616
+937
+9% +$74.1K ﹤0.01% 2995
2016
Q1 		$856 Buy
10,679
+997
+10% +$78.7K ﹤0.01% 2965
2015
Q4 		$730K Sell
9,682
-203
-2% -$32.6K ﹤0.01% 3071
2015
Q3 		$3.79M Buy
9,885
+2,294
+30% +$1.03M ﹤0.01% 2017
2015
Q2 		$3.15M Buy
7,591
+738
+11% +$309K ﹤0.01% 2216
2015
Q1 		$3.26M Buy
6,853
+3,757
+121% +$1.78M ﹤0.01% 2120
2014
Q4 		$1.15M Buy
3,096
+2,000
+182% +$515K ﹤0.01% 2758
2014
Q3 		$258K Buy
+1,096
New +$248K ﹤0.01% 3466

Other funds holding LRMR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management's LRMR Position: Q1 2026 in Review

Geode Capital Management increased its Larimar Therapeutics (LRMR) stake by 1.4% in Q1 2026, buying an estimated $61.7K and bringing the position to 1,108,761 shares worth $4.99M. The position accounts for ﹤0.01% of the portfolio, ranked #2737.

Geode Capital Management first reported a position in LRMR in Q3 2014 and has held it in 47 quarters since. The position peaked at $8.26M in Q2 2024. 162 funds tracked by Wall St. Rank hold LRMR as of Q1 2026.

  • Geode Capital Management held 1,108,761 shares of Larimar Therapeutics worth $4.99M as of Q1 2026.
  • Geode Capital Management bought 15,438 Larimar Therapeutics shares in Q1 2026, an estimated $61.7K.
  • Larimar Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #2737 holding.
  • Geode Capital Management first reported a position in Larimar Therapeutics in Q3 2014 and has held it in 47 quarters since.
  • Geode Capital Management's Larimar Therapeutics position peaked at $8.26M in Q2 2024.
  • 162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.